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OBJECTIVES The objective of this study was to use electrocardiogram (ECG)-independent parameters to
determine whether preconditioning (PC) exists in humans during percutaneous transluminal
coronary angioplasty (PTCA).
BACKGROUND Several studies suggest that both ischemia and adenosine induce PC in the human heart
during PTCA. However, because almost all of these studies relied on ST-segment shifts as
indicators of the severity of ischemia, their conclusions continue to be questioned, and the
very existence of ischemic or adenosine PC in humans remains controversial.
METHODS Eighteen patients received either intracoronary adenosine (n  9) or normal saline (n  9);
10 min later, they underwent PTCA (three 2-min balloon inflations 5 min apart).
RESULTS Compared with the first inflation, in untreated patients the second and third inflations were
associated with less systolic dysfunction (two-dimensional echocardiography), less diastolic
dysfunction (color M-mode echocardiography), less lactate production, and less H release
into the great cardiac venous blood. In adenosine-treated patients, the extent of all of these
abnormalities during the first inflation was less than in untreated patients and did not change
with subsequent inflations.
CONCLUSIONS Previous exposure to a brief episode of ischemia (first balloon inflation) or to adenosine
produces concordant decreases in ECG, subjective, mechanical, and metabolic manifestations
of ischemia during PTCA. These data support the concept that both ischemic PC and
pharmacologic PC exist in humans and that PTCA is a useful clinical setting in which to
discern their mechanism. (J Am Coll Cardiol 2003;42:437–45) © 2003 by the American
College of Cardiology Foundation
In experimental animals, brief episodes of ischemia render
the myocardium more resistant to subsequent ischemic
episodes, a phenomenon known as ischemic precondition-
ing (PC) (1–3). Because ischemic PC is the most powerful
cardioprotective intervention discovered to date, there is
considerable interest in exploiting it to protect the ischemic
myocardium in patients with coronary artery disease (1–3).
Among all of the clinical situations potentially associated
with ischemic PC, percutaneous transluminal coronary an-
gioplasty (PTCA) has been studied most extensively. Nu-
merous studies have shown that, in the course of PTCA, the
severity of myocardial ischemia (as assessed by ST-segment
elevation and chest pain) decreases with subsequent infla-
tions, suggesting the development of ischemic PC (4–10).
Percutaneous transluminal coronary angioplasty is an attrac-
tive setting for investigating the mechanism of ischemic PC
in humans because: the duration of ischemia is well defined;
measurements can be made before, during, and after isch-
emia at precise time points; pretreatment is possible; and
potentially confounding variables are minimized. Thus, if
the existence of ischemic PC during PTCA can be defini-
tively proven, this could be a useful model for gaining
insights into the mechanisms underlying cardioprotection in
humans.
A considerable body of evidence in experimental animals
suggests that adenosine plays a central role as an endoge-
nous mediator of ischemic PC (1). We have previously
found that, judging from the ST-segment shifts on the
electrocardiogram (ECG) and the severity of chest pain,
pretreatment with adenosine induces an early PC effect
against ischemia in patients undergoing PTCA (5). These
results suggest that adenosine may be useful for PC human
myocardium, a concept that may have significant therapeu-
tic implications.
Despite the data reviewed here, however, both the use of
PTCA for the study of ischemic PC and the ability of
adenosine to mimic ischemic PC in humans continue to be
questioned, based on the fact that almost all of the studies
performed to date have relied on ST-segment shifts as
indicators of the severity of ischemia (9). These changes in
cardiac repolarization are often viewed as “soft evidence” of
protection or lack thereof, and as a result, the very existence
of ischemic PC during PTCA continues to be controversial
(9). A recent study has challenged the concept that changes
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in the ST-segment shift are predictive of changes in infarct
size in experimental animals subjected to ischemic PC (11).
Thus, it remains unclear whether the attenuation of ST-
segment elevation during subsequent inflations in the course
of PTCA indicates a decrease in the severity of ischemia.
One of the earliest and most fundamental consequences
of ischemia is the development of anaerobic glycolysis,
resulting in production of lactate and H (12). Further-
more, one of the characteristic features of ischemic PC in
experimental animals is that the preconditioned myocar-
dium exhibits a reduced accumulation of lactate and H
(13–16). This appears to be a consequence of reduced
myocardial energy demands, leading to preservation of
high-energy phosphates and decreased glycolysis (1,13,14).
Accordingly, to verify the existence of PC during PTCA,
we examined whether ischemic PC and adenosine PC affect
coronary sinus blood pH and lactate levels.
The overall objective of this study was to use ECG-
independent parameters to determine whether PC exists in
humans. To this end, we compared the end points classically
used in the setting of PTCA (ST-segment shift and chest
pain) with changes in left ventricular (LV) systolic (segmen-
tal wall motion) and diastolic (LV inflow propagation rate
[Vp]) properties assessed by echocardiography and with
changes in lactate production and cardiac venous blood pH
during or after three consecutive balloon inflations in
patients undergoing PTCA. These analyses were performed
both in untreated patients and in patients pretreated with
intracoronary adenosine, which enabled us to examine both
ischemic PC and adenosine-induced (pharmacologic) PC.
We used the same protocol and the same dosage of
adenosine that were previously shown by ECG criteria to
induce PC (5).
METHODS
The patient population for this study consisted of 23
subjects referred for PTCA of an isolated obstructive lesion
(internal diameter reduction 70% by visual assessment) in
the proximal two-thirds of the left anterior descending
coronary artery. Patients were prospectively selected on the
basis of the following criteria: 1) no angiographically visible
collateral vessels; 2) no history or ECG evidence of prior
myocardial infarction in the territory supplied by the vessel
undergoing PTCA; 3) no conduction defects on the ECG;
4) no evidence of LV hypertrophy on the echocardiogram;
5) no baseline ST-segment abnormalities on the surface or
intracoronary ECG; and 6) no use of sulfonylureas. The
protocol was approved by the Institutional Review Board,
and all patients gave written informed consent.
Experimental protocol. Percutaneous transluminal coro-
nary angioplasty was performed by a standard technique as
described (5,7,10). In this single-blind study, patients were
randomly allocated to a control or an adenosine-treated
group. Adenosine (Adenocard, Fujisawa Pharmaceutical
Co., Deerfield, Illinois) was dissolved in sterile normal
saline (20 mg in 50 ml) and infused at a rate of 2 mg/min
over 10 min through a 2.2F Tracker coronary-infusion
catheter (Boston Scientific Inc., Minneapolis, Minnesota)
into the proximal coronary artery. The control group re-
ceived an equivalent volume of vehicle (normal saline). A 6F
sheath was placed in the right internal jugular vein or right
femoral vein and a 6F multipurpose catheter was advanced
and positioned in the great cardiac vein to withdraw blood
samples. The stability of the catheter position was verified
throughout the procedure by comparison of fluoroscopic
images and by contrast injection 1 to 2 min before each
blood sampling. Paired blood samples were obtained simul-
taneously from the aorta and the great cardiac vein imme-
diately before each balloon inflation, immediately after each
balloon deflation, and 2 min after the third balloon deflation
for determination of blood pH and plasma levels of lactate.
The lactate extraction ratio (LER) was calculated as: (A 
GCV/A)  100, where A  plasma lactate in the aorta and
GCV  plasma lactate in the great cardiac vein (11). After
infusion of adenosine or vehicle, the Tracker catheter was
removed. After a 10-min drug-free period, patients under-
went three balloon inflations, each lasting 120 s, inter-
spersed with 5-min periods of reperfusion.
Assessment of ST-segment shift and chest pain. The
ECG recordings were taken as previously described (5,7,10)
and analyzed by a cardiologist who had no knowledge of the
study protocol. At the end of each inflation, the intensity of
the cardiac pain was assessed using a visual-analog scale (17)
as described (5,7,10).
Echocardiographic studies. The methods for quantitating
regional wall motion on the two-dimensional echocardio-
grams have been described in detail (5,18). To assess the
consequences of ischemia on LV relaxation, the Vp was
measured at the end of each inflation as described (19).
Specifically, the slope of the color-chamber interface move-
ment in early diastole was assessed from color M-mode
echocardiography performed along a line that connects the
center of the mitral valve annulus to the LV apex in a
four-chamber view (19). The echocardiographic studies
were analyzed by an echocardiographer (M.F.S.) who had
no knowledge of the treatment.
Lactate and pH measurements. Blood samples for lactate
analysis were collected in pre-cooled tubes and centrifuged
immediately, and the plasma was stored at 20°C until
analyzed. Samples were analyzed using a commercial kit
(Boehringer, Mannheim, GMBH Diagnostica, Germany).
Abbreviations and Acronyms
ECG  electrocardiogram/electrocardiographic
GCV  great cardiac vein
LER  lactate extraction ratio
LV  left ventricular
PC  preconditioning
PTCA  percutaneous transluminal coronary angioplasty
Vp  left ventricular inflow propagation rate
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Blood gases and pH were determined in the hospital
laboratory immediately after the procedure.
Statistical analysis. All data are reported as means 
SEM. ST-segment shifts, chest pain score, chordal short-
ening, LV ejection fraction, lactate extraction, and coronary
sinus blood pH were analyzed with two-way repeated-
measures analysis of variance. Post hoc contrasts between
groups at various time points or between time points within
one group were performed with Student t tests for unpaired
or paired data, as appropriate, using the Bonferroni correc-
tion (20).
RESULTS
Nine patients in the control group and nine in the
adenosine-treated group met the criteria detailed under
Methods and had technically adequate intracoronary and
surface ECGs associated with complete resolution of isch-
emia between balloon inflations. Complete resolution of
ischemia was defined as chest pain resolution and return of
the ST-segment on the intracoronary and surface ECGs to
within 1 mm of baseline during the 5 min that elapsed
between the first, second, and third balloon inflations. Five
patients were excluded from the study because the intra-
coronary ECG signals became inadequate during balloon
inflations (three patients) or because the echocardiographic
window was not adequate to delineate the endocardial
border (two patients).
The clinical features of the control and adenosine-treated
patients are outlined in Table 1. There were no significant
differences between the two groups.
PTCA. The anatomic and hemodynamic features of the
study population are summarized in Table 2. Heart rate and
arterial blood pressure did not differ between the two groups
during the three inflations (data not shown). The rate-
pressure product was also similar (Table 2). There was no
ECG or enzymatic evidence of myocardial injury in any
patient.
ECG manifestations of myocardial ischemia. All patients
exhibited ST-segment elevation. The values reported herein
were measured at 120 s into each inflation. In the control
group, the ST-segment shift was significantly greater during
the first balloon inflation than during the second and third
inflations on the intracoronary ECG (27  5 mm vs. 16 
3 and 13  2 mm, respectively) (Fig. 1). In contrast, in the
adenosine-treated group there were no differences in the
ST-segment shift during the first, second, and third balloon
inflations on the intracoronary ECG (7  2 mm, 9  2
mm, and 6  2 mm, respectively) (Fig. 1) or on the surface
ECG (8  2 mm, 7  2 mm, and 8  2 mm, respectively)
(Fig. 1).
On the intracoronary ECG, the ST-segment shift was
significantly smaller in the adenosine-treated group than in
the control group during each of the three inflations (7  2
mm vs. 27  5 mm [74%], p  0.05, during the first
inflation; 9  2 mm vs. 16  2 mm [43%], p  0.05,
during the second; and 6  2 mm vs. 13  2 mm [53%],
p  0.05, during the third inflation) (Fig. 1). The intra-
coronary ST-segment shift recorded during the first infla-
tion in the adenosine group was significantly (p  0.05) less
than that recorded during the third inflation in the control
group (Fig. 1); as a result, the reduction in ST-segment shift
afforded by adenosine during the first inflation (74% vs.
the first inflation in control patients) was greater than that
afforded by ischemic PC during the third inflation in the
control group (53% vs. the first inflation in this group).
Table 1. Clinical Features of the Two Groups of Patients
Control
Group
(n  9)
Adenosine-
Treated
Group
(n  9)
Age (yrs) 54  3 58  3
Gender (M/F) 5/4 7/2
Hypertension 7 6
Smoking 6 6
Diabetes mellitus* 4 3
Previous CABG 0 0
Previous PTCA 0 1
Previous myocardial infarction in
non-PTCA territory
1 2
LV ejection fraction (%) 58  1† 54  2†
Anginal syndrome on admission
CCS class 1–2 7 6
CCS class 3–4 2 3
Interval between last episode of
angina and PTCA (days)
6.2  1.1 8.0  1.2
Antianginal medications
Long-acting nitrates 7 7
Calcium channel blocking agents 4 3
Beta-blocking agents 3 4
Data are means  SEM. *These patients had insulin-dependent diabetes mellitus;
none of them was on sulfonylureas. †Measured by contrast ventriculography.
CABG  coronary artery bypass graft; CCS  Canadian Cardiovascular Society;
LV  left ventricular; PTCA  percutaneous transluminal coronary angioplasty.
Table 2. Anatomic and Hemodynamic Features of the Two
Groups of Patients
Control
Group
(n  9)
Adenosine-
Treated
Group
(n  9) p Value
Vessel undergoing PTCA
LAD 9 9 NS
% Diameter stenosis
Before PTCA 80  3 86  2 NS
After PTCA 19  1 21  1 NS
Inflation pressure (atm)
Inflation 1 6.0  0.2 6.4  0.2 NS
Inflation 2 6.0  0.2 6.4  0.2 NS
Inflation 3 6.2  0.2 6.4  0.2 NS
RPP ( 103)
Inflation 1 9.5  0.9 10.7  0.8 NS
Inflation 2 9.8  1.0 10.4  0.7 NS
Inflation 3 9.4  1.0 10.5  0.7 NS
Data are means  SEM.
atm  atmosphere; LAD  left anterior descending coronary artery; PTCA 
percutaneous transluminal coronary angioplasty; RPP  rate-pressure produce (heart
rate  systolic blood pressure).
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Figure 1. ST-segment shift on the intracoronary electrocardiogram (ECG) (top), ST-segment shift on the surface ECG (middle), and chest pain score
(bottom) at the end of the first, second, and third balloon inflations in control and adenosine-pretreated patients. Brackets indicate the pairwise
comparisons that were performed. Values are means  SEM.
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On the surface ECG, the ST-segment shift was signifi-
cantly smaller in the adenosine-treated group than in the
control group during the first inflation (8  2 mm vs. 16 
5 mm, respectively; p 0.05) but did not differ significantly
between the two groups during the second and third
inflations (7  2 mm vs. 12  2 mm and 8  2 mm vs. 8
 2 mm, respectively; p  NS) (Fig. 1). The fact that the
effects of adenosine on the ST-segment shifts were less
striking on the surface than on the intracoronary ECG
probably reflects the greater sensitivity of the latter for
detecting ischemia in the perfusion bed of the PTCA artery
(5,21).
Chest pain. In the control group, the severity of chest pain
was significantly greater during the first inflation than
during the second and third inflations (74 6 mm vs. 58
6 mm and 37  7 mm, respectively) (Fig. 1). In contrast, in
the adenosine-treated group the chest pain score did not
differ significantly during the first, second, and third infla-
tions (41  8 mm, 37  8 mm, and 35  8 mm,
respectively) (Fig. 1). The chest pain score was significantly
smaller in the adenosine-treated group than in the control
group during the first inflation (44% [p  0.05]) and
during the second inflation (36% [p  0.05] (Fig. 1).
Echocardiographic and Doppler data. In the control and
adenosine-treated groups, chordal shortening in the seg-
ments that received the infusion of normal saline or aden-
osine averaged 7.9  0.3 mm and 7.8  0.3 mm before the
infusion and 8.1  0.3 mm and 8.0  0.3 mm after the
infusion, respectively. Thus, administration of adenosine
had no appreciable effect on regional LV wall motion. In the
control group, chordal shortening decreased markedly (by
66  5%) during the first balloon inflation and recovered 5
min after deflation (Fig. 2). During the second and third
inflations, the decrease in chordal shortening was signifi-
cantly less than during the first inflation (49  6% and 41
 7%, respectively; p  0.05 vs. first inflation) (Fig. 2). In
the adenosine-treated group, the reduction in chordal short-
ening during the first inflation was significantly smaller than
in the control group (48  4% vs. 65  5%, p  0.05)
(Fig. 2). Furthermore, in contrast to the control group, in
the adenosine-treated group there were no significant dif-
ferences in chordal shortening during the first, second, and
third balloon inflations (48  4%, 49  4%, and 37
 7%, respectively) (Fig. 2).
In the control group, the Vp decreased by 55  5% and
50  5% during the first and second balloon inflations,
respectively (Fig. 2). During the third inflation, the decrease
in Vp was significantly less (37  4%; p  0.05 vs. first
and second inflations) (Fig. 2). In the adenosine-treated
group, the reduction in Vp during the first inflation was
significantly smaller than in the control group (30  4%
vs. 55  5%; p  0.05) (Fig. 2). Furthermore, in contrast
to the control group, in the adenosine-treated group there
were no significant differences in the Vp during the first,
second, and third balloon inflations (30  4%, 35 
4%, and 37  4%, respectively) (Fig. 2).
Metabolic parameters (LER and pH). In all patients, the
LER was positive at baseline, reflecting lactate extraction,
and became negative immediately after balloon inflations,
reflecting lactate production (Table 3, Fig. 3). In the control
group, the LER was significantly lower after the first
balloon inflation than after the second and third inflations
(136 30% vs.77 23% and80 32%, respectively
[p  0.05]) (Fig. 3). In contrast, in the adenosine-treated
group, the LER did not change appreciably after the first,
second, and third balloon inflations (68  22%, 63 
15%, and 83  28%, respectively) (Fig. 3). The LER was
significantly higher in the adenosine-treated group than in
the control group after the first balloon inflation (68 
22% vs. 136  30%, p  0.05) (Fig. 2) and did not differ
significantly between the two groups after the second and
third inflations (63  15% vs. 77  23% and 83 
28% vs. 80  32%, respectively (Fig. 3).
In all patients, the transcardiac gradient in blood pH
([A-GCV] pH) was positive at baseline and increased
immediately after balloon inflations, reflecting a decrease in
GCV pH (Table 3, Fig. 4). In the control group, the
(A-GCV) pH was significantly greater after the first balloon
inflation than after the second and third inflations (0.15 
0.02 vs. 0.09  0.02 and 0.10  0.02, respectively [p 
0.05]) (Fig. 4). In contrast, in the adenosine-treated group
the (A-GCV) pH remained essentially unchanged after the
first, second, and third balloon inflations (0.08  0.01, 0.07
 0.01, and 0.07  0.01, respectively) (Fig. 4). The
(A-GCV) pH was significantly smaller in the adenosine-
treated group than in the control group after the first
balloon inflation (0.08  0.01 vs. 0.15  0.02, p  0.05)
(Fig. 4) and did not differ significantly between the two
groups after the second and third inflations (0.07  0.01 vs.
0.09  0.02 and 0.07  0.01 vs. 0.10  0.02, respectively)
(Fig. 4).
DISCUSSION
This study provides a comprehensive comparison of ECG,
subjective, echocardiographic, and metabolic parameters of
ischemia during PTCA. The results demonstrate that all of
these parameters are shifted in parallel during ischemic or
adenosine PC, indicating true alleviation of ischemia.
Over the past decade, the setting of PTCA has been used
extensively to investigate the mechanisms underlying the
phenomenon of PC in humans (4–10). The results of these
studies have provided numerous insights regarding the
occurrence of ischemia-induced and pharmacologically in-
duced PC. However, widespread acceptance of these con-
cepts has been hindered by persisting concern that the major
end point used in virtually all of the studies to date, namely,
the ST-segment shift on the ECG, may not necessarily be
a reliable marker of the severity of ischemia (9). This
concern has been rekindled by a recent study in which
changes in ST-segment elevation did not correlate with
changes in infarct size in rabbits (11).
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Figure 2. Chordal shortening in the ischemic/reperfused left ventricular (LV) region (upper panel) and Vp (bottom panel) at baseline; at the end of the
adenosine infusion; at the end of the first, second, and third balloon inflations (Infl-1, Infl-2, and Infl-3); immediately before the second and third inflations
(Pre-Infl-2 and Pre-Infl-3); and 5 min after the third inflation (5 post-Infl-3) in control and adenosine-treated patients. Pairwise comparisons were
performed between groups during each inflation and among inflations within each group. Values are means  SEM.
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In order to address this fundamental uncertainty that
undermines the use of PTCA as a system to study the
mechanism of PC in humans, we examined two metabolic
parameters of ischemia, namely, lactate production and
acidosis. As expected, we found that in control patients the
ischemic myocardium switched from lactate extraction to
lactate production during the first balloon inflation (Fig. 3).
Five minutes after release of the first inflation, the myocar-
dium had reverted to its baseline status of lactate extraction.
Lactate production was observed again during the second
and third balloon inflations, but the magnitude was less than
during the first inflation. Importantly, the myocardium
reverted to lactate extraction at each subsequent baseline
(before the second and third inflations), and the baseline
values of lactate extraction were similar between control and
adenosine-treated patients (Table 3). Our data are consis-
tent with those reported by Deutsch et al. (4) and
Eltchaninoff et al. (22); the major difference is that we
measured lactate production/extraction in the same patients
in which we measured ECG, subjective, and echocardio-
graphic parameters of ischemia, whereas those previous
reports (4,22) used separate subsets of patients.
In accordance with the changes in lactate extraction, in
control patients the release of the first balloon inflation was
associated with a significant fall in great cardiac vein blood
pH, which became attenuated upon release of the second
and third inflations (Table 3, Fig. 4). To the best of our
knowledge, this is the first report in humans to document
Table 3. Lactate Extraction Ratio and pH in the Great Cardiac Vein
Baseline Infl-1 Pre-Infl-2 Infl-2 Pre-Infl-3 Infl-3
Lactate Extraction Ratio (%)
Control 16  13 136  30* 19  5 77  23*† 16  7 80  32*†
Adenosine 6  11 68  22‡ 19  7 63  15 18  6 83  28
pH
Control
Aortic pH 7.36  0.01 7.40  0.01 7.38  0.010 7.38  0.01 7.38  0.01 7.40  0.01
Great cardiac vein pH 7.32  0.01 7.25  0.02 7.34  0.010 7.29  0.01 7.34  0.01 7.30  0.02
	 0.04  0.01 0.15  0.02* 0.04  0.05 0.09  0.02*† 0.04  0.04 0.10  0.02*†
Adenosine
Aortic pH 7.36  0.01 7.38  0.01 7.37  0.01 7.38  0.01 7.37  0.02 7.38  0.02
Great cardiac vein pH 7.31  0.01 7.30  0.02 7.30  0.02 7.31  0.01 7.33  0.01 7.31  0.02
	 0.05  0.01 0.08  0.01‡ 0.07  0.02 0.07  0.01 0.04  0.01 0.07  0.01
Data are means  SEM. *p  0.05 vs. baseline. †p  0.05 vs. inflation #1; ‡p  0.05 vs. control.
Figure 3. Lactate extraction ratio in the ischemic/reperfused left ventricular region at baseline; immediately after the end of the first, second, and third
balloon inflations (Infl-1, Infl-2, and Infl-3); and immediately before the second and third inflations (Pre-Infl-2 and Pre-Infl-3) in control and
adenosine-treated patients. Brackets indicate the pairwise comparisons that were performed. Data are means  SEM.
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that the fall in coronary venous blood pH decreases during
consecutive balloon inflations, suggesting that ischemic PC
reduces myocardial H production. Taken together, the
measurements of lactate production and pH demonstrate
that the first balloon inflation modified the metabolic
response of the myocardium to the second and third
inflations in a manner that is consistent with the develop-
ment of ischemic PC. Studies in experimental animals have
shown that preconditioned myocardium exhibits less lactate
production and less acidosis than non-preconditioned myo-
cardium (13–16). The mechanism responsible for this is
unclear but is thought to involve a decrease in the rate of
glycolysis as a result of downregulated energy consumption
(12–16).
We also studied a group of patients preconditioned with
adenosine. We have previously shown that this dose of
adenosine induces an early PC effect, judging from the
changes in ST-segment elevation on the intracoronary and
surface ECG and from the severity of chest pain (5). The
present study demonstrates that these salubrious actions of
adenosine are associated with parallel effects on lactate
extraction (Fig. 3) and acidosis (Table 3, Fig. 4), further
confirming the ability of adenosine to mimic ischemic PC in
the clinical setting. The data reported herein represent the
first evidence that adenosine induces the metabolic features
of the preconditioned phenotype (less accumulation of
lactate and H) in humans. In addition, this study demon-
strates that adenosine PC improves systolic function as well
as diastolic filling during ischemia.
In contrast to previous studies (22,23) in which a quali-
tative echocardiographic method was used to assess the
improvement of segmental wall motion abnormalities dur-
ing successive balloon inflations, in the present study re-
gional wall motion during successive balloon inflations was
analyzed using a quantitative method (the centerline
method) that corrects for ventricular translation (5,18).
Previous investigations have also used color M-mode
Doppler echocardiography to assess the diastolic properties
of the myocardium during PTCA (19,24). These studies
(19,24) have shown that during the acute ischemia associ-
ated with balloon inflation, LV filling is delayed and Vp (an
index of LV relaxation) decreases; however, color M-mode
Doppler echocardiography has not been studied previously
in the setting of ischemic PC. To the best of our knowledge,
the present study is the first evidence that ischemic PC
attenuates the LV relaxation abnormalities during acute
myocardial ischemia in humans.
Taken together, the results presented herein demonstrate
that two different forms of PC (ischemic PC and adenosine
PC) alleviate the severity of myocardial ischemia, as deter-
mined by six separate end points (ST-segment elevation,
chest pain severity, regional wall motion abnormalities,
diastolic abnormalities, and two metabolic indices of isch-
emia). Unlike previous investigations, all of these six vari-
ables were measured in each patient, thereby enabling us to
compare their changes in the same subjects. By using
parameters independent of the ECG (i.e., LV chordal
shortening, Vp, myocardial lactate extraction, and blood
Figure 4. Transcardiac gradient in coronary blood pH at baseline; immediately after the first, second, and third balloon inflations (Infl-1, Infl-2, and Infl-3);
and immediately before the second and third inflations (Pre-Infl-2 and Pre-Infl-3) in control and adenosine-treated patients. Because arterial pH did not
change significantly, the differences in the gradient indicate changes in great cardiac vein pH. Brackets indicate the pairwise comparisons that were
performed. Data are means  SEM. A-GCV  aorta-great cardiac vein.
444 Leesar et al. JACC Vol. 42, No. 3, 2003
PC During Coronary Angioplasty August 6, 2003:437–45
pH), we provide incontrovertible evidence that the severity
of ischemia is indeed attenuated on subsequent balloon
inflations during PTCA and that adenosine alleviates the
severity of ischemia during the first balloon inflation,
supporting the notion that both ischemic PC and pharma-
cologic PC do indeed exist in humans and that the changes
in ST-segment elevation previously described (4–10) are
truly indicative of alleviation of myocardial ischemia. The
present results have important conceptual implications. The
results have also significant methodologic implications be-
cause they support the utility of PTCA as a clinical setting
to dissect the mechanisms responsible for PC in the human
heart, although it is unlikely that the more distal events in
the signaling cascade of PC can be assessed in this model.
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